Dual dopamine agonist treatment in Parkinson's disease.

摘要: We studied the effectiveness of cabergoline as an adjunct in patients with early Parkinson’s disease receiving another dopamine agonist (pramipexole or ropinirole), at maximal permitted dose. The study enrolled 47 patients: 35 had motor fluctuations and were a dopamine with levodopa; 12, without motor fluctuations, a dopamine levodopa. These medications in all cases failed to achieve adequate symptom control. In 35 patients when was added to therapy, time spent OFF period decreased by 65.6% (from 3.14±1.11 1.08±1.07 hours p<0.0001); Unified Parkinson’s Disease Rating Scale (UPDRS) score decreased by 19.24% (from 41.68±12.6 33.66±10.22; (p<0.0001) during the condition, 7.11% 17.01±6.63 15.8±7.22; p<0.001) during ON condition. Nocturnal akinesia improved in all except one. 12 motor fluctuations, added, UPDRS score improved 34.4% 23.5±5.3 15.5±4.7). This open shows that dual therapy can be useful symptomatic treatment with early more advanced therapy with